Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems. It has presence in five European markets and a marketing partner network across developed and emerging markets. On October 1, 2012, the Company announced that it had entered into a 100 year distribution agreement with Valeant Pharmaceuticals International Inc. for the distribution of injectable aesthetic dermal filler products Sculptra and New-Fill and the sub-distribution of Succeev in Western Europe. In March 2011, the Company launched FlammaSpray for the treatment of sunburn. In November 2013, Sinclair IS Pharma PLC announced the disposal of non-core products Effederm, Xclair, Salinum and SST. In January 2014, Sinclair IS Pharma PLC acquired Obvieline Laboratories SA. In January 2014, Sinclair IS Pharma PLC acquired Atlean, a dermal filler, from Stiefel the dermatology business of GSK.